Mode
Text Size
Log in / Sign up
N/A N=50 Other

The Emotional and Functional Benefits of Poly-L-Lactic Acid

Facial Volume Loss

Enrolled (actual)
50
Serious AEs
0.0%
Results posted
May 2019
Primary outcome: Primary: Mean Subject Self Reported Quality of Life Scale — 3.45 units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Poly-L-Lactic Acid (Sculptra) injection (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Yardley Dermatology Associates
Primary completion
Jun 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean Subject Self Reported Quality of Life Scale
3.22
PRIMARY
Mean Rosenberg Self-Esteem Scale
2.24
PRIMARY
Mean Rosenberg Self-Esteem Scale
2.24
PRIMARY
Mean Subject Self Reported Quality of Life Scale
3.22

Summary

This study will evaluates the emotional and functional benefits of Poly-L-Lactic Acid (Sculptra™), a cosmetic product used to fill defects of the skin. All participants will receive Sculptra™.

Eligibility Criteria

Inclusion Criteria

  • Subject must be an outpatient, male or female subjects of any race, 35 years of age or older.
  • Subject must have any degree of facial volume loss.
  • Subjects of all Fitzpatrick skin types are eligible.
  • Subject must be able to follow study instructions and likely to complete all required visits, as assessed by the Investigator.
  • Subject must sign an IRB-approved Informed Consent form, Photographic Release Form, and the Authorization for Use and release of Health and Research Study Information (HIPAA) form prior to any study-related procedures being performed.

Exclusion Criteria

  • Any of the previous facial treatments:

c. Any facial filler in the past 2 years d. Prior injection of permanent facial implant

  • Have any skin pathology or condition that could interfere with the evaluation of the face.
  • Be unable to communicate or cooperate with the Investigator due to a language barrier (non-English speaking), poor mental development, or impaired cerebral function.
  • Have evidence of alcohol or drug abuse (Investigator opinion), or history of poor cooperation, non-compliance with medical treatment, or unreliability.
  • Have used an investigational device, biologic or drug in the past 30 days, or be currently participating in an experimental drug, biologic or device trial.
  • Have a condition or be in a situation that, in the Investigator's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study.
  • Be an employee (or a relative of an employee) of the Investigator, Sponsor or representative of the Sponsor.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02613481). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search